Business Insights: Specialty Pharmaceuticals Market Outlook
- Your Price: $3,835.00
- Add to Cart
Product Description:
What is outlook for specialty pharma companies and therapeutic markets to 2014?
This report reveals market dynamics, leading players, and key therapy areas of opportunity for specialty pharma companies. Market drivers include increasing reimbursement from national health bodies and governments, industry consolidation, big pharma divestments and biotech growth. Resistors including increased competition, big pharma entry to specialty markets and the financial crisis are also examined in the context of industry strategies of licensing deals, product acquisitions and orphan drug development. Ten leading players are profiled including an analysis of current products, drug pipelines and threats from patent expiries.
The effects of industry trends such as rising costs, and generic erosion are analyzed and developed into an outlook for the future of the specialty sector, including strategies for future success.
Click here to view a sample of this report.
Key features of this report
- Sizes the specialty pharmaceutical market and makes quantitative forecasts to 2014
- Details market drivers and resistors against the background of pharmaceutical market dynamics.
- Profiles the ten largest specialty pharma companies, including recent deals, product pipelines and key patent expiries.
- Analyzes the effects of wider pharmaceutical industry trends on specialty players.
- Details strategies for success in the future specialty pharma market.
Key benefits from reading this report
- Assess leading players in the specialty sector.
- Understand the drivers and resistors of the specialty pharmaceutical market.
- Understand key market strategies such as in-licensing, acquisitions and orphan drug development.
- Determine therapy areas of rich opportunity which are well suited to the specialty pharma business model.
- Develop strategies for success in the future specialty pharma market.
Key findings from this report
- The specialty pharmaceutical market is estimated at $116bn in 2010 and is forecast to grow to $141bn by 2014.
- In 2008, specialty pharma companies accounted for 15% of global pharmaceutical sales, and 40% of sales not accounted for by big pharma companies.
- Central nervous system, anti-infectives, cardiovascular and ophthalmology were the largest specialty pharma therapy areas in 2008.
- Industry pressures on large diversified pharma companies are having a knock-on effect on the specialty sector in the form of increased competition for licensing deals.
- Easing credit conditions will give rise to a further wave of consolidation, with specialty players likely to become acquisition targets.
Key questions answered by this report
- What is outlook for specialty pharma companies and therapeutic markets to 2014?
- What are the drivers and resistors of the specialty pharma market?
- What are the leading players in the specialty pharmaceutical sector?
- What indications and therapy areas are most ripe for entry by specialty pharma companies?
- What strategies will be successful in the future specialty pharmaceutical market?
Click here to view a sample of this report.
The report will be delivered as a PDF via e-mail. Orders must be paid in full before shipment. All sales are final; no returns or refunds are permitted with this product. For more information, please call 877/437-4276 or e-mail account manager Maureen Croce at mcroce@hcpro.com.
Product Types : Departments :
SOURCE CODE: ESEARCHGOO
